Clinical Trials · NCT00701363

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

Name: Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 4Lanreotide Octreotide

Phase: Phase 4
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 124
Start date: Oct 2008
Locations: 44 sites, 14 countries
Primary endpoint: Percentage of Subjects Having Maintained Their Injection Interval Schedule of Six Weeks or Increased Their Injection Interval to Eight Weeks Whilst Keeping Their Normalised Insulin Growth Factor (IGF-1) Levels (Age and Sex Adjusted)

View Lanreotide compound reference